chomp chomp chomp, page-10

To be up 15% and had 16 million done is a major effort.

In my opinion that is the most significant factor.

Obviously there are some major players who are wanting to get in possibly before some major news which should see the stock re rated as some of the other biotechs have done recently.

I think the name change to Rhinomed will also have a massive effect. It will signal the birth of a new company ready to launch itself onto world markets.

Its all about perception. The change of name will help it considerably in my opinion.